| Bioactivity | NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis[1][2]. | ||||||||||||
| Target | NLRX1 | ||||||||||||
| In Vivo | NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels[2].NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: | ||||||||||||
| CAS | 2389235-01-0 | ||||||||||||
| Formula | C24H21N3O3 | ||||||||||||
| Molar Mass | 399.44 | ||||||||||||
| Appearance | 粘稠液体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203(12):3407-3415. [2]. Leber A, et.al. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1 [published online ahead of print, 2019 Oct 25]. Drug Chem Toxicol. 2019;1-6. |
Amelenodor
CAS: 2389235-01-0 F: C24H21N3O3 W: 399.44
NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathw
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.